Close Sidebar
Nordic Life Science
Now Reading
Targovax starts expansion part in the phase I/II trial with ONCOS-102 in combination with durvalumab
Search for content, post, videos
Search for content, post, videos
Advertisement

Targovax starts expansion part in the phase I/II trial with ONCOS-102 in combination with durvalumab

August 5, 2019
1740 Views
Research clinical trials

All safety reviews during the dose escalation phase have been completed with no Dose Limiting Toxicities (DLT) reported and the five US hospital sites are now open for further recruitment.

This phase I/II trial investigates the safety, biologic and anti-tumor activity of ONCOS-102 in combination with Imfinzi (durvalumab, anti-PD-L1) in patients with advanced peritoneal malignancies who have failed prior standard chemotherapy and have histologically confirmed platinum-resistant or refractory epithelial ovarian or colorectal cancer.

The sponsor of the trial is Ludwig Institute for Cancer Research with coordination and funding support from the Cancer Research Institute.

Advertisement
Advertisement

Related Posts

September 11, 2014

Peptonic Medical’s applications for starting a phase 2b clinical study have been approved by the Swedish Medical Products Agency and the Central Ethical Review Board. According to the company, the aim of the study is to investigate the effect of Peptonic Medical’s product candidate Vagitocin in menopausal and post-menopausal women suffering…

October 6, 2020

Immunicum has announced that a total of 15 patients have now been enrolled in the ongoing Phase Ib/II ILIAD combination trial. In addition, ilixadencel has maintained a consistent safety profile in the study to-date and the Dose Escalation Committee (DEC) confirmed there were no dose limiting toxicities. The Phase Ib…

Jakob-Lindberg_Oncopeptides
January 20, 2017

Oncopeptides announces that the clinical development program is continuing according to plan and the company has recently initiated an additional Phase II clinical trial of Ygalo in combination with dexamethasone. The clinical trial is conducted in patients with late stage relapsed and refractory multiple myeloma (RRMM) that are refractory to…

laboratory
November 12, 2018

A1M Pharma announces that the Swedish Medical Products Agency has granted permission to start a clinical Phase I study of ROSgard – a drug candidate developed to prevent Acute Kidney Injury (AKI) in connection with primarily heart surgery. The Phase I study is expected to start during the first quarter…